Opinion|Videos|February 20, 2025
First-Line Combination Therapy for EGFR-mutated Metastatic NSCLC: Evaluating Amivantamab + Lazertinib and Osimertinib-Based Regimens.
Author(s)Misako Nagasaka, MD, PhD
The panelist discusses how, regarding the patient case, she will review the FDA approved options for the patient, including the combination of amivantamab + Lazertinib, osimertinib/chemotherapy, or single agent osimertinib.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please discuss a treatment approach for the patient case.
- Please review the evidence from MARIPOSA (amivantamab + lazertinib) and FLAURA2 (osimertinib/chemotherapy) supporting combination therapy in this setting.
Advertisement
Related to this article
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
3
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
4
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
5